Abstract: A heat pump unit control system, comprising a heat exchanger, a compressor, a first switching element, a second switching element, an enhanced vapor injection electronic expansion valve, and a main circuit electronic expansion valve. A first end of the compressor is connected to a first port of the heat exchanger by the first switching element and the enhanced vapor injection valve, a second port of the heat exchanger is connected to an injection end of the compressor, the end of the first switching element connected to the compressor is connected to a third port of the heat exchanger, a fourth port of the heat exchanger is connected to a second end of the compressor by the main circuit valve, and the end of the first switching element connected to the enhanced vapor injection valve is connected to the fourth port of the heat exchanger by the second switching element.

Abstract: A heat pump unit control system, comprising a heat exchanger, a compressor, a first switching element, a second switching element, an enhanced vapor injection electronic expansion valve, and a main circuit electronic expansion valve. A first end of the compressor is connected to a first port of the heat exchanger by the first switching element and the enhanced vapor injection valve, a second port of the heat exchanger is connected to an injection end of the compressor, the end of the first switching element connected to the compressor is connected to a third port of the heat exchanger, a fourth port of the heat exchanger is connected to a second end of the compressor by the main circuit valve, and the end of the first switching element connected to the enhanced vapor injection valve is connected to the fourth port of the heat exchanger by the second switching element.

Abstract: A method of inhibiting the activity, signaling, and/or function of a p110? mutant protein in a cancer cell expressing the p110? mutant protein includes administering to the cancer cell an amount of a therapeutic agent effective to inhibit binding of the p110? mutant protein to IRS1 in the cell.

Abstract: The present invention relates to the development of a novel assay for determining the activity of human histone deactylase 8 (HDAC8). As shown in FIG. 3, thioactyl-lysine-containing peptide is used as the substrate for the HDAC8-catalyzed dethioacetylation reaction. Thioacetate, which is formed during this reaction, is subsequently reacted with Ellman's reagent, 5,5?-dithiobis(2-nitrobenzoate), (DTNB) with a quantitative formation of 2-nitro-5-thiobenzoate (TNB). The concentration of thioacetate formed during the conversion reaction can be quantified by measuring the absorbance of TNB at 412 nm.

Abstract: The present invention relates to methods for producing inhibitors for protein deacetylases, and to the compounds and/or products produced by such methods. More specifically, the present invention relates to methods for producing inhibitors for human class III protein deacetylases or sirtuins, and to the compounds and/or products produced by such methods. The present invention provides the transformation of peptide substrates to potent peptide inhibitors by replacement of N?-thioacetyl-lysine for N?-acetyl-lysine.

Abstract: The present invention relates to yohimbine dimer compounds, pharmaceutical compositions containing such dimer compounds, methods of making such dimer compounds, and uses thereof.

Abstract: The present invention relates to yohimbine dimer compounds, pharmaceutical compositions containing such dimer compounds, methods of making such dimer compounds, and uses thereof. The yohimbine dimer compounds include compounds of formula (I): where R is any linker molecule which affords a yohimbine dimer that has activity as an &agr;2-AR antagonist and has selectivity for an &agr;2-AR subtype over another &agr;2-AR subtype.

Abstract: The present invention relates to yohimbine dimer compounds, pharmaceutical compositions containing such dimer compounds, methods of making such dimer compounds, and uses thereof.

Abstract: A device for reducing wear to the inner wall of a cyclone separator by causing a protective layer of particulate to accumulate along the inner wall. The protective layer is facilitated by securing an expanded metal sheet along the inner wall of a cyclone separator. Once formed the protective layer of particulate acts as a shield and cushion to high-energy kinetic particles as they continue to enter the cyclone separator. The high-energy particles strike the accumulated particulate without harming the inner wall of the cyclone separator.